KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBT Margin (2018 - 2025)

BioNTech SE's EBT Margin history spans 8 years, with the latest figure at 612.94% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 61295.0% to 612.94% in Q4 2025 year-over-year; TTM through Dec 2025 was 62.64%, a 6262.0% decrease, with the full-year FY2025 number at 36.61%, up 60273.0% from a year prior.
  • EBT Margin hit 612.94% in Q4 2025 for BioNTech SE, down from 1.63% in the prior quarter.
  • Over the last five years, EBT Margin for BNTX hit a ceiling of 261.45% in Q3 2024 and a floor of 5162.82% in Q2 2025.
  • Historically, EBT Margin has averaged 391.1% across 5 years, with a median of 35.12% in 2023.
  • Biggest five-year swings in EBT Margin: surged 23605bps in 2024 and later tumbled -453671bps in 2025.
  • Tracing BNTX's EBT Margin over 5 years: stood at 85.2% in 2021, then fell by -13bps to 74.16% in 2022, then tumbled by -40bps to 44.84% in 2023, then plummeted by -100bps to 0.01% in 2024, then crashed by -6715556bps to 612.94% in 2025.
  • Business Quant data shows EBT Margin for BNTX at 612.94% in Q4 2025, 1.63% in Q3 2025, and 5162.82% in Q2 2025.